← Leaderboards
Prasad S. Adusumilli
Sloan-Kettering Inst Can Research
$7,809,681
Attributed
$11,407,450
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.8M · FY2012–25$5M$3.8M$2.5M$1.3M$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,407,450 · 8
By mechanism
R01$6,896,904 · 3
UG3$3,061,861 · 1
R21$1,271,031 · 3
U54$177,654 · 1
Top collaborators
- Stephen Barnett Solomon5 shared
- Govindarajan Srimathveeravalli5 shared
- Marjorie G. Zauderer5 shared
- Camelia Sima4 shared
- Santosh Kumar Patnaik2 shared
- Vladimir Ponomarev2 shared
- Nabil Rizk2 shared
- Laura Tang2 shared
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Stephen Barnett Solomon$1,149,224
- Marjorie G. Zauderer$2,538,334
- Govindarajan Srimathveeravalli$2,024,698
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsTumorMesothelinChimeric Antigen ReceptorTranslatingT-LymphocyteMediatingInnovationSolid NeoplasmMalignant Pleural MesotheliomaMalignant NeoplasmsChimeric Antigen Receptor T CellsImmunotherapyCell PhysiologyCytotoxicT Cell TherapyAdoptive TransferNeoplastic CellImmune ResponseDoseSurface AntigensAntigensPathway InteractionsTargeted Delivery
Grant awards (23)
CD28-KITv CAR T cells with PD-1 dominant negative receptor$1,570,342
UG3 · FY2025 · CA · contact PI
Tuning KITv CAR T cells for the solid tumor environment$655,042
R01 · FY2025 · CA · contact PI
CD28-KITv CAR T cells with PD-1 dominant negative receptor$1,491,519
UG3 · FY2024 · CA · contact PI
A phase I/II combination immunotherapy clinical trial: mesothelin-targeted chimeric antigen receptor T cells and checkpoint blockade agent in pleural mesothelioma$690,978
R01 · FY2024 · CA · contact PI
Tuning KITv CAR T cells for the solid tumor environment$655,042
R01 · FY2024 · CA · contact PI
A phase I/II combination immunotherapy clinical trial: mesothelin-targeted chimeric antigen receptor T cells and checkpoint blockade agent in pleural mesothelioma$712,796
R01 · FY2023 · CA · contact PI
A phase I/II combination immunotherapy clinical trial: mesothelin-targeted chimeric antigen receptor T cells and checkpoint blockade agent in pleural mesothelioma$712,796
R01 · FY2022 · CA · contact PI
Image-guided irreversible electroporation directed CAR T-cell delivery to solid tumors$402,618
R01 · FY2022 · CA · contact PI
Image-guided irreversible electroporation directed CAR T-cell delivery to solid tumors$410,835
R01 · FY2021 · CA · contact PI
A phase I/II combination immunotherapy clinical trial: mesothelin-targeted chimeric antigen receptor T cells and checkpoint blockade agent in pleural mesothelioma$1
R01 · FY2021 · CA · contact PI
A phase I/II combination immunotherapy clinical trial: mesothelin-targeted chimeric antigen receptor T cells and checkpoint blockade agent in pleural mesothelioma$727,344
R01 · FY2020 · CA · contact PI
Image-guided irreversible electroporation directed CAR T-cell delivery to solid tumors$410,835
R01 · FY2020 · CA · contact PI
A phase I/II combination immunotherapy clinical trial: mesothelin-targeted chimeric antigen receptor T cells and checkpoint blockade agent in pleural mesothelioma$727,344
R01 · FY2019 · CA · contact PI
Image-guided irreversible electroporation directed CAR T-cell delivery to solid tumors$398,509
R01 · FY2019 · CA · contact PI
Image-guided irreversible electroporation directed CAR T-cell delivery to solid tumors$392,764
R01 · FY2018 · CA · contact PI
Imaging the efficacy of TRAIL-enhanced cancer immunotherapy$187,920
R21 · FY2018 · CA
Imaging the efficacy of TRAIL-enhanced cancer immunotherapy$225,504
R21 · FY2017 · CA
Full PROJ 1: Preclinical Evaluation, Clinical Trial Preparation and a Prospectiv$95,655
U54 · FY2014 · CA · contact PI
Validation of a risk model for stage I lung adenocarcinoma$190,021
R21 · FY2013 · CA · contact PI
Mesothelin as a biomarker for clinical management of esophageal adenocarcinoma$186,970
R21 · FY2013 · CA · contact PI
Full PROJ 1: Preclinical Evaluation, Clinical Trial Preparation and a Prospectiv$81,999
U54 · FY2013 · CA · contact PI
Validation of a risk model for stage I lung adenocarcinoma$241,931
R21 · FY2012 · CA · contact PI
Mesothelin as a biomarker for clinical management of esophageal adenocarcinoma$238,685
R21 · FY2012 · CA · contact PI